Poliomyelitis: Videos & Practice Problems

Poliomyelitis is caused by the poliovirus, a non-enveloped RNA picornavirus that is also an enterovirus. Infection usually begins in the throat or small intestine after fecal-oral spread, often through contaminated water. The virus can infect pharyngeal or intestinal epithelial cells, spread to lymph nodes or blood, and cause viremia. If it reaches motor neurons in the brain stem and spinal cord, it can damage these cells and lead to paralysis, including respiratory paralysis.

Most infections are asymptomatic, but illness can range from minor flu-like symptoms to non-paralytic disease with viral meningitis, and in severe cases to paralytic polio. Diagnosis is based on detecting or isolating the virus from feces or throat secretions, including PCR testing for viral RNA. Treatment is mainly supportive care rather than a single consistently effective antiviral therapy.

Prevention depends on vaccination against all three serotypes. The IPV is an inactivated polio vaccine preferred where polio has been eradicated because it is extremely safe. The OPV is an oral attenuated vaccine often preferred where polio is still spreading because it provides stronger, longer-lasting immunity and helps reduce transmission, although in very rare cases it can revert to virulence.

Poliomyelitis

Poliomyelitis, commonly known as polio, is caused by the poliovirus, a non-enveloped RNA virus belonging to the Picornaviridae family. The name "picornavirus" derives from "pico," meaning very small, and "RNA," indicating that it is a small RNA virus. Polio historically caused widespread paralysis, with severe cases requiring devices like iron lungs to assist breathing due to respiratory muscle paralysis. Thanks to effective vaccination programs initiated in the 1950s and 1960s, polio has been eradicated in many countries, including the United States since 1979, though it remains endemic in some regions worldwide.

The poliovirus is classified as an enterovirus, meaning it primarily infects the gastrointestinal tract. Infection begins in the throat or small intestine, where the virus targets epithelial cells. There are three main serotypes of poliovirus—types 1, 2, and 3—necessitating vaccination against all three to ensure comprehensive immunity. After initial infection, the virus can spread to lymph nodes and enter the bloodstream, a condition known as viremia. From the bloodstream, poliovirus can invade motor neurons in the brainstem and spinal cord, potentially causing paralysis.

Transmission occurs via the fecal-oral route, often through contaminated water sources. This mode of spread explains historical concerns about swimming pools and other communal water bodies. The clinical presentation of polio varies widely. Approximately 90% of infected individuals remain asymptomatic. About 5% experience minor polio with flu-like symptoms, while roughly 2% develop non-paralytic polio characterized by viral meningitis symptoms such as neck stiffness and muscle spasms. Viral meningitis from polio is typically self-limiting and rarely fatal.

The most severe form, paralytic polio, arises when the virus infects and destroys motor neurons, leading to muscle weakness and paralysis. Paralysis can affect limbs or respiratory muscles, sometimes necessitating mechanical ventilation. Recovery varies; some patients regain function, while others suffer permanent disability.

Diagnosis involves isolating the virus from fecal samples or throat secretions, with modern techniques including polymerase chain reaction (PCR) to detect viral RNA. Treatment is primarily supportive, as no antiviral therapy effectively cures polio. Supportive care focuses on managing symptoms and preventing complications.

Immunity against poliovirus is achieved through vaccination, which remains the cornerstone of polio prevention. Two main vaccines exist: the inactivated polio vaccine (IPV), preferred in polio-free regions like the United States, and the oral polio vaccine (OPV), used in areas where polio is still endemic. The IPV contains killed virus particles and is administered via injection, while the OPV contains live attenuated virus and is given orally. Both vaccines stimulate immunity against all three poliovirus serotypes, playing a critical role in global polio eradication efforts.

The Polio Vaccine

The story of polio is closely tied to the development of two main types of polio vaccines: the inactivated polio vaccine (IPV) and the oral polio vaccine (OPV). The IPV, also known as the Salk vaccine after Jonas Salk who developed it in 1955, uses an inactivated (killed) poliovirus. This type of vaccine is extremely safe because the virus cannot replicate or cause disease. In contrast, the OPV, or Sabin vaccine named after Albert Sabin who developed it in the 1960s, contains a live attenuated (weakened) virus. This live virus can replicate in the intestines and provide strong immunity, sometimes even spreading to others in the community to indirectly vaccinate them.

The key difference between these vaccines lies in their safety and immunity profiles. The IPV is administered via injection, requiring sterile syringes and trained healthcare workers, which increases cost and complexity. It provides immunity that prevents polio disease but does not stop the virus from replicating in the intestines or spreading to others. Therefore, while it protects the vaccinated individual, it does not completely halt transmission in a community.

On the other hand, the OPV is given orally as drops, often on sugar cubes, making it easy and inexpensive to administer, especially in low-resource or rural settings. It induces a robust, often lifelong immunity that prevents both disease and viral spread. However, because it contains a live virus, there is a very rare risk—approximately one in a million—that the attenuated virus can mutate back to a virulent form capable of causing paralysis. Despite this risk, the benefits of OPV in areas with active polio transmission outweigh the potential downsides.

In countries where polio has been eradicated and healthcare systems are well-developed, the IPV is preferred due to its safety and the low risk of virus circulation. Conversely, in developing countries or regions where polio is still endemic, the OPV is favored because it provides stronger community immunity and is easier to distribute widely. This strategic use of vaccines has been crucial in the global effort to control and eventually eradicate polio.

Understanding the differences between inactivated and attenuated vaccines highlights important concepts in immunology and public health, such as vaccine safety, herd immunity, and disease transmission dynamics. The IPV and OPV exemplify how vaccine design and administration methods must be tailored to the epidemiological context to maximize effectiveness and minimize risks.

Which is the most common outcome of polio infection?

• A. Paralysis.
• B. Meningitis.
• C. Flu-like symptoms.
• D. Asymptomatic infection.

Answer: (D)

Historically, some people who contracted polio had to use an “iron lung”. Why was this intervention necessary?

• A. Poliovirus infects and damages motor neurons of the brain stem and spinal cord, including those that control breathing.
• B. Meningitis caused by polio causes increased pressure on the neurons that control breathing.
• C. Polio toxin causes paralysis, including of the diaphragm, requiring assistive breathing.
• D. Polio infection damages the neuromuscular junction, blocking the release of neurotransmitters that stimulate breathing.

Answer: (A)

For a country or region that has eradicated polio, which vaccine is generally preferred for use and why?

• A. IPV: it provides longer-lasting immunity.
• B. IPV: as an inactivated vaccine, it is generally considered safer.
• C. OPV: along with preventing disease, it prevents the spread of disease.
• D. OPV: it is far cheaper to administer on a per-dose basis.

Answer: (B)

Here's what students ask on this topic:

What is poliomyelitis and how does the poliovirus cause disease?

Poliomyelitis, commonly known as polio, is a viral infection caused by the poliovirus, a non-enveloped RNA picornavirus classified as an enterovirus. The infection typically begins in the throat or small intestine after the virus enters the body through the fecal-oral route, often via contaminated water. The virus infects epithelial cells in the digestive tract, then spreads to lymph nodes and the bloodstream, causing viremia. If the virus reaches motor neurons in the brain stem or spinal cord, it can destroy these cells, leading to paralysis. Symptoms vary widely, from asymptomatic cases to minor flu-like illness, viral meningitis, or severe paralytic disease affecting limbs or respiratory muscles. The severity depends on whether the virus invades the nervous system and damages motor neurons.

What are the main symptoms and stages of poliomyelitis infection?

Poliomyelitis symptoms range from none to severe paralysis. About 90% of infected individuals are asymptomatic. Around 5% experience minor polio with flu-like symptoms such as fever and malaise. Approximately 2% develop non-paralytic polio, which involves viral meningitis characterized by neck stiffness, muscle spasms, and flu-like symptoms. The most severe form is paralytic polio, where the virus infects motor neurons in the brain stem and spinal cord, causing muscle weakness or paralysis. Paralysis can affect limbs or respiratory muscles, sometimes requiring mechanical ventilation (iron lung). Recovery varies; some regain function, while others have permanent paralysis. Understanding these stages is crucial for diagnosis and management.

How is poliomyelitis diagnosed and treated?

Diagnosis of poliomyelitis involves isolating the poliovirus from feces or throat secretions. Modern methods include PCR testing to detect viral RNA, which is sensitive and specific. Since symptoms can mimic other diseases, laboratory confirmation is important. Treatment is primarily supportive, as there is no specific antiviral therapy effective against polio. Supportive care includes managing symptoms, preventing complications, and providing respiratory support if paralysis affects breathing muscles. Rehabilitation may be necessary for patients with paralysis. Early diagnosis and supportive treatment improve outcomes, but prevention through vaccination remains the most effective strategy.

What are the differences between the inactivated polio vaccine (IPV) and the oral polio vaccine (OPV)?

The inactivated polio vaccine (IPV), also known as the Salk vaccine, contains killed poliovirus and is administered via injection. It is extremely safe and preferred in countries where polio has been eradicated. IPV induces immunity that prevents disease but does not fully stop intestinal infection or virus transmission, so vaccinated individuals can still spread the virus. The oral polio vaccine (OPV), or Sabin vaccine, contains live attenuated virus given as oral drops. OPV induces strong, long-lasting immunity and prevents both disease and virus transmission. It is easier and cheaper to administer, making it ideal for developing countries with ongoing polio transmission. However, in rare cases (about 1 in a million), OPV can revert to a virulent form and cause paralysis. The choice of vaccine depends on the epidemiological context.

Why is vaccination critical for polio eradication, and what challenges remain?

Vaccination is essential for polio eradication because it prevents infection, disease, and virus transmission. Immunization against all three poliovirus serotypes is necessary for full protection. The IPV is used in polio-free countries due to its safety, while OPV is used in endemic areas for its ability to induce herd immunity and interrupt transmission. Challenges include vaccine-derived poliovirus cases from OPV, logistical difficulties in reaching all populations, and maintaining high vaccination coverage. Continued global efforts focus on surveillance, vaccination campaigns, and addressing vaccine hesitancy to achieve complete eradication.